Evaluation of brain and nerve pathology in rats chronically dosed with ddI or isoniazid

Neurotoxicology and Teratology

Volumn 18, Issue 5, 1996, Pages 555-563

  Schmued, Larry C ^a   Albertson, Christopher M ^a,b   Andrews, Annette ^a   Sandberg, Jennifer A ^a   Nickols, Jess ^c   Slikker Jr , William ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c John L McClellan Mem Med Center   (United States)

Author keywords

AIDS drugs; Isoniazid ddI; Neuropathology; Rat; Tuberculosis drugs

Indexed keywords

DIDANOSINE; ISONIAZID; MYELIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ELECTROPHYSIOLOGY; HISTOLOGY; MALE; MICROSCOPY; NEUROPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; RODENTIA;

EID: 0030250580     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/0892-0362(96)00088-8     Document Type: Article

References (36)

1. 1. Anderson, T. D.; Davidovich, A.; Arceo, R.; Brosnan, C.; Arezzo, J.; Schaumburg, H. H. Peripheral neuropathy induced by 2′,3′-dideoxycytidine, A rabbit model of 2′,3′-dideoxycytidine neurotoxicity. Lab. Invest. 66:63-74; 1991.
2. 2. Anderson, T. D.; Davidovich, A.; Feldman, D.; Sprinkle, T. J.; Arezzo, J.; Brosnan, C.; Calderon, R. O.; Fossom, L. H.; DeVries, J. T.; DeVries, G. H. Mitochondrial Schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity. Lab. Invest. 70:724-739; 1994.
3. 3. Barns, P. F.; Bloch, A. B.; Davidson, P. T.; Snider, D. E. Tuberculosis in patients with the human immunodeficiency virus infection. N. Engl. J. Med. 324:1644-1650; 1991.
4. 4. Barrio, E.; Caballo, E.; Cabarcos, A. Prevalence of tuberculosis and the use of isoniazid prophylaxis in alergic HIV-infected patients. AIDS 8:857-858; 1994.
5. 5. Bayer, R.; Dubler, N. N.; Landsman, S. The dual epidemics of tuberculosis and AIDS: Ethical and policy issues in screening and treatment. Am. J. Public Health 83:649-654; 1993.
6. 6. Blakemore, W.F. Isoniazid. In: Spencer, P.; Schaumberg, H., eds. Experimental and clinical neurotoxicology. Baltimore: Williams and Wilkins; 1980:476-489.
7. 7. Blakemore, W. F.; Palmer, A. C.; Noel, P. R. B. Ultrastructural changes in isoniazid-induced brain oedema in the dog. J. Neurocytol. 1:263-174; 1972.
8. 8. Braun, M. M.; Byers, R. H.; Heyware, W. L.; Ciesielsky, C. A.; Bloch, A. B.; Berkelman, R. L.; Snider, D. E. Acquired immunodeficiency syndrome and extrapulmonary tuberculosis in the United States. Arch. Intern. Med. 150:1913-1916; 1990.
9. 9. Cavanagh, J. B. On the pattern of change in peripheral nerves produced by isoniazid intoxication in rats. J. Neurol. Neurosurg. Psychiatry 30:26-33; 1967.
10. 10. Connolly, K. J.; Allan, J. D.; Fitch, H.; Jackson-Pope, L.; McLaren, C.; Canetta, R.; Grooprnan, J. E. Phase I study of 2′,3′-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to Zidovudine. Am. J. Med. 471-478; 1991.
11. 11. Feldman, D.; Brosnan, C.; Anderson, T. Ultrastructure of peripheral neuropathy induced in rabbits by 2′,3′-dideoxycytidine. Lab. Invest. 66:75-84; 1992.
12. 12. Harper, K. H.; Worden, A. N. Comparative toxicity of isonicotinic acid hydrazide and its methanosulfonate derivative. Toxicol. Appl. Pharmacol. 8:325-333; 1966.
13. 13. Jacobs, J. M.; Miller, R. H.; Cavanagh, J. B. Studies on the early changes in acute isoniazid neuropathy in the rat. Acta. Neuropathol. 47:85-92; 1979.
14. 14. Kieburtz, K. D.; Seidlin, M.; Lambert, J. S.; Dolin, R.; Reichman, R.; Valentine, F. Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-relaled complex treated with Dideoxyinosine. J. Acquir. Immune Defic. Syndr. 5:60-64; 1992.
15. 15. Klinghart, E. W. Experimentelle nervenfaserchadigungen durch isonicitinsaurehydrazine und ihre bedeutung fur die klinik. Verh. Dtsch. Ges. Inn. Med. 60:764-787; 1954.
16. 16. LeLacheur, S. F.; Simon, G. L. Exacerbation of dideoxyctidine-induced neuropathy with dideoxyinosine. J. Acquir. Immune Defic. Syndr. 4:538-539; 1991.
17. 17. Mitsuya, H.; Broder, S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′-dideoxynucleosides. Proc. Natl. Acad. Sci. USA 83:1911-1915; 1989.
18. 18. Mitsuya, H.; Yarchoan, R.; Broder, S. Molecular targets for AIDS therapy. Science 249:1533; 1990.
19. 19. Moyle, G. J.; Nelson, M. R.; Hawkins, D.; Gazzard, B. G. The use and toxicity of didanosine (ddI) in HIV antibody positive individuals intolerant to zidovudine (AZT). Q. J. Med. 86:155-163; 1993.
20. 20. Noel, P. R. B.; Wordan, A. N.; Palmer, A. C. Neuropathologic effects and comparative toxicity for dogs of isonicotinic acid hydrazide and its methanosulfonate derivative. Toxicol. Appl. Pharmacol. 30:337-349; 1967.
21. 21. Ochoa, J. Isoniazid neuropathy in man: Quantitative electron microscopic study. Brain 93:831-835; 1970.
22. 22. Saag, M. S. Nucleoside analogues: Adverse effects. Hosp. Prac. 27:26-36; 1992.
23. 23. Sandberg, J. A.; Schmued, L. C.; Fogel, M. C.; Ferguson, S. A.; Nickols, J.; Paule, M. G.; Slikker Jr., W. Neurotoxicity assessment of the anti-HIV therapeutic 2′,3′-dideoxyinosine (ddI) in the rat. Pharmacologist 35:152:1993.
24. 24. Schlaepfer, W. W.; Hager, H. Ultrastructural studies of INH-induced neuropathy in rats: I early axonal changes. Am. J. Pathol. 45:209-219; 1964.
25. 25. Schlaepfer, W. W.; Hager, H. Ultrastructural studies of INH-induced neuropathy in rats. II Alteration and decomposition of the myelin sheath. Am. J. Pathol. 45:423-433; 1964.
26. 26. Schlaepfer, W. W.; Hager, H. Ultrastructural studies of INH-induced neuropathy in rats: III repair and regeneration. Am. J. Pathol. 45:679-689; 1964.
27. 27. Schmued, L. C. A rapid sensitive histochemical stain for myelin in frozen brain sections. J. Histochem. Cytochem. 38:717-720: 1990.
28. 28. Simpson, D. M.; Tagliati, M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J. AIDS 9:153-161; 1995.
29. 29. Singlas, E.; Taubret, A. M.; Lebas, F. B.; Parent de Curzon, O.; Sobel, A.; Chauveau, P.; Viron, B.; Al Khayat, R.; Poignet, J. L.; Mignon, F.; Humbert, G.; Fillastre, J. P. Didanosine pharmacokinetics in patients with normal and impaired renal function: Influence of hemodialysis. Antimicrob. Agents Chemother. 36:1519-1524; 1992.
30. 30. Spencer, P. S.; Foster. G. V.; Sterman, A. B.; Horoupain, D. Acetyl ethyl tetralin. In: Spencer, P. S.; Schaumberg, H. H., eds. Experimental and clinical neurotoxicology. Baltimore: Williams & Wilkins; 1980:303-308.
31. 31. Weinstein, L. Drugs used in the chemotherapy of leprosy and tuberculosis. In: Goodman, L.; Gilman, A., eds. The pharmacological basis of therapeutics. London: The Macmillan Co.: 1970:1324-1328.
32. 32. Winder, F. G.; Collins, P. B. Inhibition by isoniazid of synthesis of mycolic acids in mycobacterium tuberculosis. J. Gen. Microbiol. 63:41-48; 1970.
33. 33. Yarchoan, R.; Hiroaki, M.; Thomas, R. V.; Pluda, J. M.; Hartman, N. R.; Perno, C. F.; Marczyk, K. S.; Allain, J. P.; Johns, D. G.; Broder, S. In vivo activity against HIV and favorable toxicity profile of 2′,3′-didoexyinosine. Science 45:412-415; 1989.
34. 34. Yarchoan, R.; Mitsuya, H.; Pluda, J. M.; Marczyk, K. S.; Thomas, R. V.; Hartman, N. R.; Brouwers, P.; Perno, C. F.; Allain, J. P.; Johns. D. G.; Broder, S. The National Cancer Institute Phase I study of 2′,3′-dideoxyinosine administration in adults with AIDS-related complex: Analysis of activity and toxicity profiles. Rev. Infect. Dis. 12:522-533; 1990.
35. 35. Yarchoan, R.; Pluda, J. M.; Perno, C. F.; Mitsuya, H.; Thomas, R. V.; Wyvill, K. M.; Broder, S. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann. NY Acad. Sci. 616:328-343; 1990.
36. 36. Yarchoan, R.; Pluda, J. M.; Thomas, R. V.; Mitsuya, H.; Browers, P.; Wyvill, K. M.; Hartman, N.; Johns, D. G.; Broder, S. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex. Lancet 336:526-529; 1990.